MIMEDX Announces Third Quarter 2026 Operating & Financial Results
Globe Newswire•28/10/2026•16:03 ET
1
Key Highlights
- ➤Q3 net sales $62.3 million, down 45% year over year
- ➤2026 net sales outlook $250-$260 million
- ➤Surgical product sales increased 9% year over year
- ➤Wound sales decreased 71% year over year amid Medicare changes
- ➤Patent license agreement provides $25 million in five $5 million installments
Expert Statements
Joseph H. Capper, Chief Executive Officer of MIMEDX
“Our third quarter results reflect the progress we have made in reshaping MIMEDX into a Surgical-led company with a leaner cost structure that returned us to positive Adjusted EBITDA.”
Joseph H. Capper, Chief Executive Officer of MIMEDX
“Our Surgical franchise delivered mid-teens volume growth against a strong prior-year comparison and softer U.S. surgical procedure volumes.”
Joseph H. Capper, Chief Executive Officer of MIMEDX
“While a few discrete items dampened reported Surgical sales growth of 9% in the quarter, underlying demand remained strong across the portfolio, and Surgical now represents nearly two-thirds of our net sales.”
Joseph H. Capper, Chief Executive Officer of MIMEDX
“As the Wound Care market works through a sluggish reset, we are beginning to see the anticipated signs of adjustment, including patient migration into Wound Care Centers, where MIMEDX unit volume grew 7% sequentially in the quarter.”
Joseph H. Capper, Chief Executive Officer of MIMEDX
“We continue to believe the market will ultimately favor established manufacturers that have scale and prioritize investment in robust clinical research.”
Joseph H. Capper, Chief Executive Officer of MIMEDX
“With our cost actions from earlier this year now fully reflected in our run rate, we delivered a significant sequential improvement in our GAAP net loss and a return to positive Adjusted EBITDA in the quarter.”
Joseph H. Capper, Chief Executive Officer of MIMEDX
“We are working diligently with the FTC to obtain HSR clearance and look forward to completing the acquisition of Sanara MedTech.”
Joseph H. Capper, Chief Executive Officer of MIMEDX
“As we prepare for the combination of the two companies, our conviction in both the strategic rationale and the financial merits of this transaction remains strong.”
Reports Continued Double-Digit Year-Over-Year Volume Growth for Surgical Franchise
Delivers Wound Care Center Volume Growth Both Sequentially and Year-Over-Year
Get started
Create a free account to read the full story.